Processing

Please wait...

Settings

Settings

1. WO2009054873 - ANTI-RANTES ANTIBODIES AND METHODS OF USE THEREOF

Publication Number WO/2009/054873
Publication Date 30.04.2009
International Application No. PCT/US2008/009382
International Filing Date 04.08.2008
IPC
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
06
produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C12P 21/06 (2006.01)
A61K 38/16 (2006.01)
C07K 16/18 (2006.01)
CPC
A61K 2039/505
C07K 16/24
C07K 2317/21
C07K 2317/30
C07K 2317/33
C07K 2317/52
Applicants
  • NOVIMMUNE S.A. [CH/CH]; 14 Ch. Des Aulx CH-1228 Plan-les-ouates, CH (AllExceptUS)
  • FISCHER, Nicolas [CH/CH]; CH (UsOnly)
  • KOSCO-VILBOIS, Marie [US/FR]; FR (UsOnly)
  • MACH, Francois [CH/CH]; CH (UsOnly)
Inventors
  • FISCHER, Nicolas; CH
  • KOSCO-VILBOIS, Marie; FR
  • MACH, Francois; CH
Agents
  • ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC One Financial Center Boston, MA 02111, US
Priority Data
60/963,27102.08.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-RANTES ANTIBODIES AND METHODS OF USE THEREOF
(FR) ANTICORPS ANTI-RANTES ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
(FR)
L'invention porte sur des anticorps monoclonaux entièrement humains, et sur des fragments de ceux-ci, qui se lient à la chimiokine régulée lors de l'activation, exprimée par des lymphocytes T normaux et sécrétée (RANTES, CCL5), modulant ainsi l'interaction entre RANTES et un ou plusieurs de ses récepteurs, tels que, par exemple, CCR1, CCR3, CCR4 et CCR5, et/ou modulant les activités biologiques de RANTES. L'invention porte également sur l'utilisation de ces anticorps anti-RANTES ou n'importe quels anticorps anti-RANTES dans la prévention ou le traitement de troubles apparentés à l'immunité et dans l'amélioration d'un ou plusieurs symptômes associés à un trouble apparenté à l'immunité.
Other related publications
Latest bibliographic data on file with the International Bureau